The United States is currently at an inflection point in Hepatitis C virus (HCV) response. We have the tools for rapid and accurate diagnosis, safe and effective cure, and prevention. These tools are only as useful as access to them can be, which is why the Cure Hepatitis C Act (S.1941) holds so much promise.
Forty-five years ago the Centers for Disease Control and Prevention (CDC) published a brief report describing five cases of a rare pneumonia among young gay men in Los Angeles. The report occupied just a few paragraphs in the Morbidity and Mortality Weekly Report (MMWR). No one reading it could have known that it marked the beginning of one of the deadliest epidemics in modern history.
TAG and KNCV are excited to present an upcoming webinar: Using Digital Storytelling and AI for Active Drug Safety Monitoring in Tuberculosis Care on Tuesday, June 20, at 9 a.m. EST. This is the latest installment in the series of virtual trainings for community and civil society organizations hosted by TAG under the Unitaid-funded ASCENT DR-TB Project.
TAG and the Long-Acting Therapies Community Advisory Board (LAT CAB) welcomed a decision by the Indian Patent Office rejecting a patent application related to the hepatitis C treatment combination glecaprevir/pibrentasvir (G/P). Advocates say the decision could help reduce barriers to generic competition, lower treatment costs, and expand access to hepatitis C treatment in low- and middle-income countries disproportionately affected by the epidemic.
Treatment Action Group (TAG) is profoundly troubled by recent reporting that the NIH’s longstanding Notice of Funding Opportunity (NOFO) process is being interrupted and delayed by political interference.
The collapse of global health aid in 2025 revealed the fragility of health financing. Despite successes against TB and HIV in recent years, health aid has not generated sustainable, country-led financing for health. Now, governments are scrambling to fill funding gaps to provide life-saving care.
The Promise and Potential of Economic Reforms for Health The collapse of global health aid in 2025 revealed the fragility of health financing. Despite successes against TB and HIV in recent years, health aid from bilateral and multilateral donors has…
Huge congratulations to TAG’s Executive Director Mark Harrington for winning a Wakefield Outstanding Dedication Award presented by the HIV Trials Network (HVTN)! The HVTN, the largest publicly funded collaboration facilitating HIV/AIDS vaccine evaluations, presents the Wakefield Award to public health champions who demonstrate exceptional service and contribution to HIV vaccine research.
TAG is hiring! We are looking for a dynamic, experienced communications coordinator to work closely with our tuberculosis (TB) project team. Learn more and apply here!
Treatment Action Group’s (TAG) HIV team works across the country to achieve a shared mission: end the HIV epidemic through science, policy, and advocacy. As a remote team, the reach is national but the urgency is personal. At a time when progress is possible and precarious, the team ensures that research translates into action for impacted communities.
Your donation will bring progress, healing, and hope — turning the promise of innovative research into a brighter, healthier future for all.
